AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
TG Therapeutics Announces $100M Share Buyback Plan
ByAinvest
Thursday, Sep 4, 2025 1:52 am ET1min read
TG Therapeutics announced a $100M share buyback program, allowing the company to purchase shares through open-market transactions. The program reflects its commitment to generating shareholder value.
New York, Sept. 02, 2025 — TG Therapeutics, Inc. (NASDAQ: TGTX) has announced a new share repurchase program worth up to $100 million. This move reflects the company's commitment to generating shareholder value and underscores its confidence in the current market conditions.The new program, authorized by the company's Board of Directors, will allow TG Therapeutics to buy back shares through open-market purchases and other transactions, in accordance with applicable securities laws and subject to market conditions. This initiative follows the successful completion of the company's previously authorized $100 million share repurchase program, which was completed in August 2025.
Under the completed program, TG Therapeutics repurchased approximately 3.5 million shares of its common stock at an average price of $28.55 per share. The new program aims to continue this trend by acquiring up to an additional $100 million of TG Therapeutics' common stock.
Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, "We are pleased to announce the completion of our previously authorized $100 million share repurchase program. In the month of August, we were able to repurchase approximately $78 million of TG stock at what we believe were highly attractive prices. In addition, our Board of Directors has authorized a new $100 million repurchase program, underscoring our continued commitment to delivering value to shareholders and reflecting our conviction that current market prices do not adequately reflect the multibillion-dollar potential of BRIUMVI or the long-term growth prospects of TG Therapeutics."
The share buyback program is a strategic move that could potentially increase earnings per share and provide investors with a higher return on investment. It also signals the company's confidence in its financial health and future growth prospects.
References:
[1] https://seekingalpha.com/news/4491936-tg-therapeutics-launches-100m-share-buybacks
[2] https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-completion-existing-share-repurchase
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet